Oaktop Capital Management Ii LP Cut Its Celgene Corp Com (CELG) Position by $8.02 Million

November 10, 2018 - By Richard Conner

Celgene Corporation (NASDAQ:CELG) LogoInvestors sentiment decreased to 0.71 in Q2 2018. Its down 0.08, from 0.79 in 2018Q1. It turned negative, as 68 investors sold CELG shares while 495 reduced holdings. 98 funds opened positions while 300 raised stakes. 476.86 million shares or 7.08% less from 513.18 million shares in 2018Q1 were reported. The California-based Symphony Asset Mngmt Limited Com has invested 0.26% in Celgene Corporation (NASDAQ:CELG). 3,019 were accumulated by North Star Asset Mgmt. Moreover, Loeb Prtnrs has 0.13% invested in Celgene Corporation (NASDAQ:CELG). Moreover, Manchester Mngmt Ltd Limited Liability Company has 0.12% invested in Celgene Corporation (NASDAQ:CELG). Buckingham Asset Mngmt Ltd holds 2,970 shares. The New York-based First Long Island Limited Company has invested 0.73% in Celgene Corporation (NASDAQ:CELG). Destination Wealth Management reported 0% in Celgene Corporation (NASDAQ:CELG). Tru Of Oklahoma, Oklahoma-based fund reported 20,647 shares. Clarivest Asset Mngmt Lc has 0.32% invested in Celgene Corporation (NASDAQ:CELG). Lenox Wealth holds 0% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 151 shares. Envestnet Asset Mngmt reported 66,007 shares stake. Acadian Asset Mgmt Ltd Liability Corporation owns 3,532 shares. Tower Cap Limited (Trc) owns 43,845 shares. Bangor Bank & Trust holds 0.23% or 14,892 shares in its portfolio. Perigon Wealth Mgmt Llc invested in 1.3% or 36,083 shares.

Since June 4, 2018, it had 0 insider purchases, and 2 sales for $2.43 million activity. 13,000 shares valued at $1.02 million were sold by CASEY MICHAEL D on Thursday, June 7.

Oaktop Capital Management Ii Lp decreased its stake in Celgene Corp Com (CELG) by 4.69% based on its latest 2018Q2 regulatory filing with the SEC. Oaktop Capital Management Ii Lp sold 101,559 shares as the company’s stock rose 12.17% with the market. The hedge fund held 2.06 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $163.99M, down from 2.17M at the end of the previous reported quarter. Oaktop Capital Management Ii Lp who had been investing in Celgene Corp Com for a number of months, seems to be less bullish one the $51.76 billion market cap company. The stock decreased 1.61% or $1.21 during the last trading session, reaching $74.02. About 4.13M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 38.90% since November 10, 2017 and is downtrending. It has underperformed by 54.52% the S&P500.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “3 Cancer Stocks to Watch in December” on November 07, 2018, also Seekingalpha.com with their article: “Celgene Does Not Have A Growth Catalyst – Cramer’s Lightning Round (11/6/18)” published on November 07, 2018, Nasdaq.com published: “Waiting for bluebird bio to Sing at ASH” on November 09, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Does Celgene Tickle Your Buygene?” published on October 30, 2018 as well as Seekingalpha.com‘s news article titled: “Celgene Corporation 2018 Q3 – Results – Earnings Call Slides” with publication date: October 25, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 6 analysts covering Celgene (NASDAQ:CELG), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Celgene has $16300 highest and $91 lowest target. $118.67’s average target is 60.32% above currents $74.02 stock price. Celgene had 8 analyst reports since May 23, 2018 according to SRatingsIntel. Morgan Stanley maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, July 13. Morgan Stanley has “Equal-Weight” rating and $91 target. The rating was upgraded by Standpoint Research to “Buy” on Monday, June 18. The stock has “Buy” rating by Oppenheimer on Friday, May 25. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Bernstein on Wednesday, May 23. The firm has “Hold” rating given on Wednesday, May 23 by Argus Research. The rating was maintained by Morgan Stanley on Friday, July 27 with “Equal-Weight”. The stock of Celgene Corporation (NASDAQ:CELG) has “Hold” rating given on Thursday, May 31 by Cantor Fitzgerald.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>